Genetic alterations in malignant melanoma

Diagnostic Histopathology

Volumn 16, Issue 7, 2010, Pages 317-320

  Held, Matthew A ^a,b   Bosenberg, Marcus W ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF; CDKN2A; melanoma; mutations; PTEN; RAS

Indexed keywords

ALPHA INTERFERON; BETA CATENIN; CORTICOTROPIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACARBAZINE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 2; INTERMEDIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOPHENOL MONOOXYGENASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN; TEMOZOLOMIDE; TYROSINASE RELATED PROTEIN 1; WNT PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER INCIDENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; DISEASE COURSE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; MELANOCYTE; MELANOGENESIS; MELANOMA; METASTASIS POTENTIAL; SIGNAL TRANSDUCTION; ULTRAVIOLET RADIATION;

EID: 77953233478     PISSN: 17562317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2010.03.001     Document Type: Article

References (25)

1. Gray-Schopfer V., Wellbrock C., and Marais R. Melanoma biology and new targeted therapy. Nature 445 (2007) 851-857
2. Markovic S.N., Erickson L.A., Rao R.D., et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc 82 (2007) 490-513
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
4. Tsao H., Atkins M.B., and Sober A.J. Management of cutaneous melanoma. N Engl J Med 351 (2004) 998-1012
5. Pleasance E.D., Cheetham R.K., Stephens P.J., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463 (2010) 191-196
6. Dankort D., Curley D.P., Cartlidge R.A., et al. Braf (V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41 (2009) 544-552
7. Held M.A., Curley D.P., Dankort D., McMahon M., Muthusamy V., and Bosenberg M.W. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res 70 (2010) 388-397
8. Platz A., Egyhazi S., Ringborg U., and Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 1 (2008) 395-405
9. Omholt K., Platz A., Kanter L., Ringborg U., and Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9 (2003) 6483-6488
10. Bennet D. How to make a melanoma: what do we know of the primary clonal events?. Pigment Cell Melanoma Res 21 (2008) 27-38
11. Bastian B.C., LeBoit P.E., and Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 157 (2000) 967-972
12. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
13. Michaloglou C., Vredeveld L.C., Soengas M.S., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
14. Smalley K.S., and Flaherty K.T. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol 5 (2009) 775-778
15. Jiang X., Zhou J., Yuen N.K., et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 14 (2008) 7726-7732
16. Bastian B.C., LeBoit P.E., Hamm H., Brocker E.B., and Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58 (1998) 2170-2175
17. Lahtz C., Stranzenbach R., Fiedler E., Helmbold P., and Dammann R.H. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J Invest Dermatol 130 (2010) 620-622
18. Goldstein A.M., Chan M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44 (2007) 99-106
19. Yu H., McDaid R., Lee J., et al. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol 174 (2009) 2367-2377
20. Chin L., Garraway L.A., and Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20 (2006) 2149-2182
21. Polakis P. Wnt signaling and cancer. Genes Dev 14 (2000) 1837-1851
22. Goding C.R. Melanocyte development and malignant melanoma. Forum (Genova) 10 (2000) 176-187
23. Rimm D.L., Caca K., Hu G., Harrison F.B., and Fearon E.R. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154 (1999) 325-329
24. Box N.F., Duffy D.L., Chen W., et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69 (2001) 765-773
25. Duffy D.L., Zhao Z.Z., Sturm R.A., Hayward N.K., Martin N.G., and Montgomery G.W. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 130 (2010) 520-528